The association between polypharmacy and the development of frailty is unknown. The present study assessed the longitudinal relationship between polypharmacy and frailty risk in Japanese community-dwelling older adults.
Introduction
The increase in the population of older adults is a global concern. In particular, the population of older adults is increasing rapidly in Asian countries. 1 Physical frailty is an intermediate state between
well-being and the need for nursing care. 2 Preventing frailty is essential to avoid a crisis within Japan's social security program. Thus, the search for risk factors for frailty is important. Polypharmacy is associated with adverse events, such as falls, hospitalization and mortality. 3 Polypharmacy is also a risk factor for skeletal muscle loss. 4 The Asia-Pacific Clinical Practice guidelines for the management of frailty strongly recommend that polypharmacy be addressed by reducing or stopping the prescribing of any inappropriate and/or superfluous medications. 5 Previous studies also showed that polypharmacy was associated with a higher development of frailty in community-dwelling Australian, French, German and North American older adults. [6] [7] [8] [9] Although polypharmacy is associated with falls and cognitive impairment, it is unclear whether polypharmacy is a risk factor for physical frailty among Japanese older adults. 10, 11 The present study investigated the longitudinal relationship between polypharmacy and frailty risk in community-dwelling older Japanese adults.
Methods

Participants
The present study included older adults who participated in the National Institute for Longevity Sciences-Longitudinal Study of Aging (NILS-LSA). The NILS-LSA is a population-based biennial survey of a dynamic cohort of approximately 2300 persons, and it is a prospective study that started in November 1997. 12 Participants in the NILS-LSA were randomly selected from registered residents, and stratified according to both sex and decade of age.
12
The Ethics Committee of the National Center for Geriatrics and Gerontology approved the study protocol. All participants provided written informed consent for participation in the present study.
Baseline participants in the present study included 598 older adults aged 65-81 years who completed the second-wave examinations of the NILS-LSA between April 2000 and May 2002. They also completed the bodyweight measurement at the firstwave examination (November 1997 to April 2000). Of these individuals, 312 (52.2%) participated in the 6-year follow-up examination (NILS-LSA fifth-wave examination; from July 2006 to July 2008).
Participants with frailty in the second-wave examination were excluded to examine the longitudinal association between the development of frailty and number of medications. Finally, 299 older adults were included in this study.
Number of medications
All prescribed and non-prescribed medications used during the previous 2 weeks of the baseline examination were brought in by participants and documented. Medications were confirmed and coded based on Japan standard commodity classification by physicians. The total number of medications was used to define the exposure.
Frailty assessment
Frailty assessment was carried out based on a modification of the Cardiovascular Health Study (CHS) criteria 13 for older Japanese adults 14 at the baseline and follow-up examinations. Frailty was assessed using the following five criteria: shrinking, exhaustion, weakness, low activity and slowness. Frailty was defined as meeting three or more of these criteria, pre-frailty was defined as meeting one or two criteria and robust was defined as having none of these criteria. Shrinking was assessed by unintentional weight loss in the previous 2 years. Height and weight were measured using digital scales. The weight loss rate was calculated based on weight data in the previous 2 years. The cut-off for shrinking was 5% of unintentional weight loss in men and women. These criteria are a modification of the original criteria in the CHS. 13, 14 Exhaustion was assessed by a self-report, which included two questions from the Center for Epidemiologic Studies of Depression scale: "You felt that everything you did was an effort" and "You could not get going." Responses included "Most or all of the time," "Occasionally or a moderate amount of time," "Some or a little of the time" and "Rarely or none of the time." If participants did not answer "Rarely or none of the time" to these questions, they were defined as having exhaustion. This criterion was used in the original criteria in the CHS to assess exhaustion. 13 Weakness was assessed by grip strength, which was measured using a handgrip dynamometer (T.K.K.4301a, Takei, Niigata, Japan). The maximum value from four trials for both hands was recorded. The cut-off for weakness was 26 kg in men and 18 kg in women. This criterion was a modification of the original criterion in the CHS. 13, 14 The level of leisure physical activity was used to assess low activity. Trained interviewers used a questionnaire modified from the Minnesota Leisure-time Physical Activity Questionnaire to assess physical activity using questions regarding activity intensity and frequency over the preceding year. The mean total-time and leisure-time physical activity per day was calculated (metabolic equivalents × min/day). Low activity was defined as the lowest 20% of leisure-time physical activity by sex, which was the same as the original criterion in the CHS. 13 Slowness was assessed by a comfortable gait speed. Gait speed was measured using a 10-m walk test. The start and end were determined with light sensors (YW-3; Yagami, Aichi, Japan). The cut-off for slowness was 1.0 m/s in men and women. This criterion was a modification of the original criterion in the CHS.
13,14
Other variables
At baseline examination, the percentage of body fat was assessed by dual-energy X-ray absorptiometry (QDR-4500; Hologic, Marlborough, MA, USA). Clinical psychologists and trained psychology graduate students carried out the Mini-Mental State Examination test. Cut-off scores of the Mini-Mental State Examination of 23 points and the Center for Epidemiologic Studies of Depression scale of 16 points were considered to represent dementia and depression, respectively. Data regarding current smoking habits and medical history were assessed using self-completed questionnaires and were confirmed by a physician after a medical examination. The number of comorbidities was defined as the sum of a history of cancer, ischemic heart disease, other heart diseases excluding ischemic heart disease, cerebrovascular disease, dyslipidemia, hypertension, diabetes, renal disease, hepatic disease, chronic bronchitis, anemia, osteoporosis, rheumatic arthritis, dementia and depression. In addition, employment and education history (years) were assessed using self-completed questionnaires.
Statistical analysis
Data are presented as mean AE standard deviation. The CochranMantel-Haenszel test was used as the trends test for categorical variables between the number of medications (≤5 vs ≥6).
Receiver operating characteristic (ROC) curve analyses were used to calculate the area under the curve for the number of medications to determine the cut-off for identifying frailty. Sensitivity and specificity were also calculated. The optimal cut-off was obtained using the Youden Index, which represents the maximum potential effectiveness of a marker.
Multiple logistic regression models were also fit to determine the associations of polypharmacy with frailty using the adjusted models with confounders. Model 1 was adjusted for sex and age at baseline (years; continuous variable). Model 2 was adjusted for sex, age, body fat (continuous variable), total physical activity (continuous variable), education (continuous variable), employment (working, not working), current smoking (no, yes) and the number of comorbidities (continuous variable). In addition, the logistic regression analysis inputting frailty status (robust or prefrailty) at baseline was used as an additional confounder in model 2.
All statistical analyses were carried out using SAS 9.3 (SAS Institute, Cary, NC, USA). P-values <0.05 were considered statistically significant.
Results
A total of 286 participants (159 men and 127 women) dropped out of the study. Among the dropouts, the mean age and the number of medications at baseline were 73.1 AE 4.5 years and 4.5 AE 3.6, respectively. Among dropouts, the age and number of medications at baseline were significantly higher than among participants who completed both examinations (t-test, P < 0.01). Participants using six or more medications included 99 dropouts and 72 non-dropouts (χ 2 -test, P < 0.01). Of these, participants using ≥10 medications included 30 dropouts and 14 non-dropouts (χ 2 -test, P < 0.01). Among the participants who dropped out, 91, 182 and 13 participants were in the robust, pre-frailty and frailty groups, respectively. Among the participants who completed the study, 134, 165 and 13 participants were in the robust, pre-frailty and frailty groups, respectively (χ 2 -test, P < 0.05). The mean AE standard deviation follow-up period was 6.2 AE 0.2 years. Table 1 presents the baseline characteristics of the 299 participants. Exhaustion based on the frailty criteria was the most common characteristic among the study participants. The mean age and number of medications of the participants was 70.6 years (range 65.0-81.0 years) and 3.5 (range 0-18), respectively. Medication exposure was 81.3% among the study participants. Figure 1 shows the relationship between the number of medications at baseline and the development of frailty at follow up. Although the development of frailty was <10% among participants taking five or fewer medications, the development of frailty was elevated among participants taking six or more medications (P for trend <0.01). Figure 2 shows the results of the ROC curve analysis. For frailty, the cut-off shown by the Youden Index was five out of six medications. The specificity was higher than the sensitivity when the cut-off was defined as five out of six medications. Table 2 shows the results of the logistic regression to determine the associations of polypharmacy with frailty. Significant associations between participants taking six or more medications and frailty were noted in model 1 (P = 0.0004) and model 2 (P = 0.0004). Modeling the number of medications as a continuous variable in model 2, the odds ratio for a development of frailty with an increase in one medication was 1.11 (95% confidence interval 0.98-1.26; P = 0.115). These results did not differ substantially after inputting the frailty status (robust or pre-frailty) at baseline into the analysis models (data not shown).
Discussion
The present study showed a relationship between polypharmacy and physical frailty in older Japanese adults. Participants taking six or more medications were more likely to develop frailty regardless of the number of comorbidities. Previous studies reported that frailty is caused by polypharmacy in older adults. [6] [7] [8] [9] In older Japanese adults, polypharmacy has been shown to lead to falls. 10 The results of the present study are consistent with previous studies and suggest that polypharmacy might be a risk factor for frailty in Japanese community-dwelling older adults. The present study showed a relationship between frailty and polypharmacy among community-dwelling older adults based on a 6-year follow-up period. In an 8-year longitudinal study with sample sizes >4000, the cumulative risk of frailty development with polypharmacy increased as the follow-up period extended. 8 Thus, long-term exposure to polypharmacy appears to be a risk factor for the development of frailty. However, short-term exposure to polypharmacy might also be a risk. For example, studies with <5 years of follow up reported that polypharmacy was associated with adverse drug reactions, falls, fractures and hospitalization. 3 Studies to determine whether short-term exposure to polypharmacy increases the risk of frailty are required.
In the present study, the ROC analysis considered five out of six medications as the cut-off for frailty; however, the area under the curve was approximately 65%. Previous studies reported that the areas under the ROC curve ranged from 58% to 70%. 6, 7 The cut-off for medications associated with development of frailty in those studies was six or more medications. 6, 7, 9 Furthermore, The Japan Geriatric Society considers taking five to six medications as polypharmacy. 15 A fall risk was associated with taking five or more medications among outpatients. 10 Taking six or more medications was associated with the risk for adverse drug reactions in patients. 16 Thus, it might be reasonable to consider taking six or more medications as a risk factor for frailty. The relationship between polypharmacy and frailty can be explained in several ways. Polypharmacy might lead to low adherence and taking the wrong medications. 15 In addition, adverse reactions to some drugs are the same as some of the criteria for frailty. For example, the cholinesterase inhibitors and the osmotic cathartics might induce weight loss and muscle weakness, respectively. 15 Furthermore, the prescribing cascade is associated with the relationship between polypharmacy and frailty. 8 It is unclear whether reducing the number of medications decreased the development of frailty in the present study. A previous study using a larger sample than the present study reported a dose-response relationship between the number of medications and frailty development, and suggested that reducing the number of medications could decrease the risk for frailty. 8 In the present study, no dose-response relationship between the number of medications and frailty development was observed (P = 0.115). These conflicting results might be caused by racial differences among study participants. For example, it is known that there are racial differences in the frequency of genetic polymorphisms in cytochrome (CY) P450, such as CYP2C19, 17 CYP2C9 18 and CYP2D6, 19 each of which is associated with the metabolism of different drugs. Furthermore, in the present study, there were 14 participants with hyper-polypharmacy (≥10 medications) who continued with the study, whereas 32 participants with hyperpolypharmacy dropped out. Thus, the analysis that modeled the number of medications as continuous might be statistically underpowered. Further study is necessary to determine whether reducing the number of medications can reduce the risk for frailty among older Japanese adults. No. medications
Development of frailty (%)
P for trend <0.01 The present study had several limitations. First, the number of dropouts might have biased the study. Second, it is unknown whether a specific medication or a specific combination of medications increased the risk for frailty, because the sample size for the analysis of the relationship between specific medications and frailty development was too small. Third, the Charlson Comorbidity Index, which is associated with adverse outcomes, was not used for the assessment of comorbidities, because the variables necessary for calculating the Charlson Comorbidity Index were not acquired in the NILS-LSA. 20 Furthermore, the duration of participants' use of medications was not known. For example, an acute medical episode at the baseline examination might have temporarily increased the number of medications. Further studies that focus on these limitations might help clarify the relationship between frailty and polypharmacy.
In conclusion, the present study evaluated the association between polypharmacy and physical frailty in community-dwelling older Japanese adults over an approximately 6-year period. Our results confirm that polypharmacy (≥6 medications) significantly increases the risk for frailty in older Japanese adults. The findings might provide information that can be used to help prevent frailty. Model 1: adjusted for sex and age at baseline. Model 2: adjusted for sex, age, body fat, employment, education years, smoking habit, total physical activity, number of comorbidities (cerebrovascular disease, ischemic heart disease, other heart diseases excluding ischemic heart disease, cancer, diabetes, hypertension, dyslipidemia, renal disease, hepatic disease, chronic bronchitis, anemia, osteoporosis, rheumatic arthritis, dementia and depression). In addition, the logistic regression analysis inputting frailty status (robust or pre-frailty) at baseline was used as an additional confounder in model 2. CI, confidence interval; OR, odds ratio.
